Modeling cancer treatment side effects using patient blood samples
Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events
This study is trying to see how cancer treatments affect the body by using blood samples from patients to create special cells that can help researchers understand side effects like heart and nerve damage.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Jacksonville, Florida) |
| Trial ID | NCT06640010 on ClinicalTrials.gov |
What this trial studies
This observational study aims to generate induced pluripotent stem cells (iPSCs) from patients undergoing cancer treatment to model and understand the adverse effects associated with cancer therapies. By differentiating these iPSCs into relevant cell types such as cardiomyocytes and neurons, researchers will investigate the mechanisms behind toxicities like cardiotoxicity and neurotoxicity. The study will also explore whether specific genetic variants in patients contribute to these toxicities and screen for potential protective therapies. Blood samples will be collected, and medical records will be reviewed to support these objectives.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are planned to receive or are currently undergoing potentially toxic cancer therapies.
Not a fit: Patients who are unable to understand the informed consent process or comply with the study protocol may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to personalized approaches in managing and mitigating cancer therapy-related side effects for patients.
How similar studies have performed: While the use of iPSCs in modeling diseases is established, this specific approach to understanding cancer therapy-related toxicities is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any patient \>= 18 years of age * Previously treated, planned or currently receiving any potentially toxic cancer therapy including but not limited to chemotherapy, targeted and immunotherapies Exclusion Criteria: * Inability on the part of the patient to understand the informed consent or be compliant with the protocol
Where this trial is running
Jacksonville, Florida
- Mayo Clinic in Florida — Jacksonville, Florida, United States (Recruiting)
Study contacts
- Principal investigator: Nadine Norton, PhD — Mayo Clinic
- Study coordinator: Clinical Trials Referral Office
- Email: mayocliniccancerstudies@mayo.edu
- Phone: 855-776-0015
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.